Impact of first‐line infliximab on the pharmacokinetics of second‐line vedolizumab in inflammatory bowel diseases
Claire Liefferinckx, Denis Franchimont(McGill University Health Centre), Wouter Van Moerkercke, Ann Gils(KU Leuven), Sophie Tops(KU Leuven), Bram Verstockt(Universitair Ziekenhuis Leuven), Séverine Vermeire(KU Leuven)
Cited by 12
Related Papers
Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease
|Nature|2012|4.8k
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci
|Nature Genetics|2010|2.6k
ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications
|Journal of Crohn s and Colitis|2018|1.8k